Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole Oral vs IV Acid Output in GERD
NCT00635414Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2002
- Primary completion
- Oct 2002
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of esomeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Maximal Acid Output at Day 20. Started Aug 2002; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00635414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00635414.